[Retracted] Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer

Table 5

Evaluation of adverse reactions (, %).

Adverse reactions	Total incidence	Incidence of grades 3-5 adverse reactions
Fatigue	20 (62.50)	2 (6.25)
Rash	10 (31.25)	0 (0.00)
Hypothyroidism	8 (25.00)	0 (0.00)
Hyperuricemia	6 (18.75)	0 (0.00)
Renal insufficiency	5 (15.63)	0 (0.00)